Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931823 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Conjupro Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 8
- Study locations
NCT04931823: Active Phase 1 study of Solid Tumor, sponsored by Conjupro Biotherapeutics.
NCT04931823 is a Phase 1 study of Solid Tumor that is active but no longer recruiting, run by Conjupro Biotherapeutics. The registered enrollment target is 126 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04931823, a Phase 1 study of Solid Tumor, is active but no longer recruiting, sponsored by Conjupro Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult patients with advanced solid tumors.
Primary Outcome
Incidence of dose-limiting toxicities (DLT) during the DLT evaluation period. DLTs assessed per CTCAE v5.0, include grade ≥ 4 neutropenia, thrombocytopenia, anemia; grade ≥ 3 febrile neutropenia, nausea, vomiting, diarrhea, skin rash, fatigue, infusion reaction; any other grade ≥ 2 non-hematologic toxicity judged to be dose limiting; and treatment delay \>14 days due to unresolved toxicities.
Conditions Studied
Interventions
- DRUG CPO-100
Study Locations (8)
California
- University of California Los Angeles - Los Angeles
Connecticut
- Yale University School of Medicine - Yale Cancer Center - New Haven
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
North Carolina
- Carolina BioOncology Institute - Huntersville
Ohio
- The Cleveland Clinic Foundation - Lyndhurst
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 1 |
What the registry record for NCT04931823 still lists
NCT04931823 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which CPO-100 is the first listed.
NCT04931823 lists 8 locations in 8 states (California, Connecticut, Nevada).
Frequently Asked Questions
What is clinical trial NCT04931823 about?
NCT04931823 is a clinical study titled "Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors". This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) in adult ...
What is the current status of trial NCT04931823?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2021-03-24. Estimated completion is 2025-03-01.
What conditions does trial NCT04931823 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04931823?
The interventions under investigation include: CPO-100 (DRUG).
Who is sponsoring clinical trial NCT04931823?
This trial is sponsored by Conjupro Biotherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04931823 being conducted?
This trial has 8 study locations across California, Connecticut, Nevada, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04931823's enrollment target sits among peer trials
126 70th of 196 higher than 127 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI